Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s):
Quarter Results
03.05.2012 / 07:45
---------------------------------------------------------------------
Berlin, May 03, 2012. The Eckert & Ziegler Group (ISIN DE0005659700), a
specialist for isotope applications in medicine, science and industry
continued its successful performance in the first three months of 2012. As
compared to the first quarter of 2011, sales revenues rose by EUR 1.0
million (+4%) to EUR 29.2 million. Profits after taxes and minority
interests were roughly the same as during the last four quarters, reaching
EUR 2.5 million or EUR 0.47 per share.
The Isotope Products segment accounts for the greatest share of total
results. Here sales revenues generated from external customers declined
slightly by 1% to EUR 14.0 million. Compared to the same quarter last year,
there were slight cost increases, so that EBIT fell by 4% from EUR 4.7
million to EUR 4.5 million. This effect was offset by lower interest
payments and taxes, so that the segment's earnings before minority
interests remained constant at EUR 3.1 million.
The Environmental Services segment showed the strongest growth. Sales
revenues from external customers surged by 44% to EUR 1.7 million. The
segment generated EBIT of EUR 0.1 million.
The 8% growth in sales revenues in the Radiation Therapy segment (to EUR
7.2 million) was also gratifying. Here the new generation of afterloaders
accounted for a rise in sales revenues, while the implants to combat
prostate cancer continued to deliver constant sales revenues. Extensive
information on the Radiation Therapy segment can be found in the Eckert &
Ziegler BEBIG s.a. quarterly report, which appears simultaneously with this
report (www.bebig.eu).
Growth slowed in the Radiopharma segment. Thanks to the Bioscan acquisition
in mid-2011, sales revenues grew by 2% in the segment to EUR 6.4 million.
In comparison to the unusually strong first quarter of 2011, EBIT fell by
67% to EUR 0.5 million.
To read the full report please click here:
http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/engl
isch/euz112e.pdf
The board of directors and supervisory board will suggest a dividend of
0.60 per share at the Annual General Meeting on 24th May 2012.
Sales of approx. EUR 117 million and a result after tax and minority
interests of approx. EUR 10 million are expected for the fiscal year 2012.
With around 590 employees the Eckert & Ziegler Group belongs to the largest
providers of isotope components for radiotherapy and nuclear medicine
worldwide.
If you have any questions please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de
End of Corporate News
---------------------------------------------------------------------
03.05.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP News-Service
---------------------------------------------------------------------
167760 03.05.2012
